Homology Medicines to Participate in Conferences in October
September 30, 2019 08:49 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations at the following industry, investor and...
Homology Medicines to Participate at Upcoming Investor Conferences
September 03, 2019 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming...
Homology Medicines Reports Second Quarter 2019 Financial Results and Recent Highlights
August 08, 2019 16:15 ET
|
Homology Medicines, Inc.
- Phase 1/2 pheNIX Study of HMI-102 Gene Therapy Candidate for Adults with PKU Continues, Additional Sites Enrolling and Initial Data Expected by Year End - - Fast Track Designation...
Homology Medicines to Participate at Upcoming Conferences
August 01, 2019 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a fireside chat at...
Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors
July 15, 2019 16:01 ET
|
Homology Medicines, Inc.
- Celgene Executive with Early- and Late-Stage Global Clinical Development Experience Joins as Homology Advances Lead Gene Therapy Program for PKU Through the Clinic - BEDFORD, Mass., July 15, 2019 ...
Homology Medicines Announces Leadership Updates
June 27, 2019 16:01 ET
|
Homology Medicines, Inc.
- Sam Rasty, Ph.D., Departs as Chief Operating Officer to Lead an Emerging Biotech - BEDFORD, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines...
Homology Medicines Presents Data Showing Single Dose HMI-102 Resulted in Long-Term Correction of PKU, Including Reduction of Phe and Increased Brain Neurotransmitters in Murine Model
June 17, 2019 07:05 ET
|
Homology Medicines, Inc.
- Phase 1/2 pheNIX Study of Gene Therapy Candidate HMI-102 is Underway and Initial Clinical Data is Anticipated by Year End - BEDFORD, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Homology Medicines,...
Homology Medicines to Present at JMP Securities Life Sciences Conference
June 13, 2019 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the JMP Securities...
Homology Medicines Initiates Phase 1/2 Study for HMI-102 Gene Therapy Candidate for Adults with PKU and Expects Initial Clinical Results by Year End 2019
June 10, 2019 08:30 ET
|
Homology Medicines, Inc.
- Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU - BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines...
Homology Medicines Announces FDA Fast Track Designation for HMI-102 Gene Therapy Development Candidate for Adults with PKU
May 14, 2019 09:00 ET
|
Homology Medicines, Inc.
- Company Provides Details of pheNIX, the First Gene Therapy Trial for PKU, and Remains on Track to Report Initial Clinical Results from the Phase 1/2 Study in 2019 - BEDFORD, Mass., May 14, 2019 ...